Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation

BACKGROUND In allogeneic hematopoietic stem cell (HSC) transplantation, the collection of an appropriate number of HSCs while maintaining a high level of safety for healthy donors is fundamental. Inadequate HSC mobilization can be seen with the standard use of granulocyte–colony‐stimulating (G‐CSF). Plerixafor (PL) is a chemokine receptor CXC Type 4–stromal‐derived factor 1 inhibitor; its HSC‐mobilizing properties are synergistic with G‐CSF in poor mobilizing patients. The use of PL as adjuvant or alternative to G‐CSF in healthy donors has shown a good safety profile but is so far off‐label. STUDY DESIGN AND METHODS We report 10 healthy HSC donors treated with PL because of insufficient response to G‐CSF alone or contraindication to G‐CSF. Eight donors did not mobilize enough CD34+ cells with G‐CSF alone because poor mobilizers or because insufficient HSCs were harvested according to the clinical need of the patient; in two cases G‐CSF administration and marrow harvest were unfeasible or contraindicated in the donor. RESULTS The use of PL for mobilization increased the number of circulating CD34+ cells by 2.8‐fold and the CD34+/kg collection by 3.0‐fold. Only mild adverse events were reported (bone pain or discomfort) and not univocally attributable to PL. Rate of engraftment and graft‐versus‐host disease were similar to those seen in recipients of grafts from G‐CSF only–mobilized donors. CONCLUSION We exposed 10 allogeneic donors to mobilization with PL. PL was well tolerated in all cases and ensured procurement of an adequate graft for transplantation resulting in a normal hematopoietic engraftment.